Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay
UBS Upgrades Gilead, Sees EPS Upside In 2019
Apr 10, 2019, 11:17 AMAnalysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Mar 22, 2019, 1:30 PMUBS: Buy Biogen For Pipeline, M&A Potential
Jan 31, 2018, 9:29 AM